|  |
| --- |
| Table N: Characteristics of studies reporting the association between Iscador® preparations and OS or event-free survival |
| **Author,****Year** | **Study Design** | **Control Group Type**(parallel, except stated otherwise) | **Indication** | **Stratum**(FIGO, except described otherwise) | **Outcome** | **Maximum Follow-up** | **Sample**(mistletoe / control) | **Host tree** |
| Longhi, 2014 [38] | RCT | internal  | osteosarcoma | IV, 2nd relapse | PRDFS | 73 months | 9 / 11 | P |
| Bar-Sela, 2013 [37] | RCT | internal  | lung | III A,B | OS | >2 years | 11 / 14 | Qu |
| Bar-Sela, 2013 [37] | RCT | internal  | lung | IV | OS | until death | 22 / 25 | Qu |
| Tröger, 2013 [33] | RCT | internal  | pancreas | III/IV | OS | 14 months | 110 / 110 | Qu |
| Zänker, 2012 [36] | RCS | internal  | colorectal | I-III | MFS | 133 months | 106 / 212 | Qu |
| Matthes, 2010 [35] | RCS | internal  | pancreas | I-IV | OS | ≥3 years | 201 / 195 | n.a. |
| Grossarth-Maticek, 2008 [29] | PCS | internal  | corpus uteri | I A-C | OS | >5 years | 103 / 103 | n.a. |
| Grossarth-Maticek, 2008 [29] | PCS | internal  | corpus uteri met | IV A,B | OS | >5 years | 95 / 95 | n.a. |
| Grossarth-Maticek, 2008 [29] | RCT | internal  | corpus uteri met | III A-IV B | OS | >5 years | 26 / 26 | n.a. |
| Grossarth-Maticek, 2008 [29] | RCT | internal  | corpus uteri | I A-C | OS | >5 years | 30 / 30 | n.a. |
| Grossarth- Maticek, 2007 [26] | PCS | internal  | ovar | I A-C | OS | >5 years | 75 / 75 | n.a. |
| Grossarth-Maticek, 2007 [26] | PCS | internal  | ovar met | IV | OS | >5 years | 62 / 62 | n.a. |
| Grossarth-Maticek, 2007 [26] | RCT | internal  | ovar met | IV | OS | >5 years | 20 / 20 | n.a. |
| Grossarth-Maticek, 2007 [26] | RCT | internal  | ovar  | I A-C | OS | >5 years | 21 / 21 | n.a. |
| Grossarth-Maticek, 2007a [27] | PCS | internal  | skin | I-II 4 ≤ BD ≤ 0.75 | OS | >5 years | 32 / 32 | n.a. |
| Grossarth-Maticek, 2007a [27] | RCT/PCS | internal  | skin | IB-II BD > 1.50 | OS | >5 years | 22 / 22 | n.a. |
| Grossarth-Maticek, 2007 b [28] | PCS | internal  | cervical | I B-IV A | OS | >5 years | 102 / 102 | n.a. |
| Grossarth-Maticek, 2007 b [28] | PCS | internal  | cervical met | IV B | OS | >5 years | 66 / 66 | n.a. |
| Grossarth-Maticek, 2007 b [28] | RCT | internal | cervical met | IV A,B | OS | >5 years | 19 / 19 | n.a. |
| Grossarth-Maticek, 2006 a [25] | PCS | internal  | breast | I-II B | OS | >5 years | 84 / 84 | n.a. |
| Grossarth-Maticek, 2006 a [25] | RCT | internal | breast | I-II B | OS | >5 years | 38 / 38 | n.a. |
| Grossarth-Maticek, 2006 b [48] | RCT | internal  | breastlymph | III A, III B | OS | >5 years | 17 / 17 | n.a. |
| Grossarth-Maticek, 2006 b [48] | PCS | internal  | breast recurrence | I, II A,B, III B | OS | >5 years | 42 / 42 | n.a. |
| Grossarth-Maticek, 2006 b [48] | PCS | internal  | breast lymph | II B, III A, III C | OS | >5 years | 55 / 55 | n.a. |
| Grossarth-Maticek, 2006 b [48] | PCS | internal  | breast met | IV | OS | >5 years | 83 / 83 | n.a. |
| Augustin, 2005[47] | RCS | internal  | skin | II, III | OS | ≥3 years | 329 / 357 | P, M, Qu |
| Bock, 2004 [46] | RCS | internal  | breast | I-III | OS | until death | 710 / 732 | n.a. |
| Grossarth-Maticek, 2004 [24] | PCS | internal  | various | I-IV | OS | >5 years | 175 / 175 | n.a. |
| Kleeberg, 2004 [49] | RCT | internal  | skin | II  B / III | OS | 8.2 years | 102 / 102 | M |
| Grossarth-Maticek, 2001 [22] | PCS | internal  | various | I-IV | OS | >5 years | 396 / 396 | n.a. |
| Grossarth-Maticek, 2001 [22] | RCT | internal  | various | I-IV | OS | >5 years | 39 / 39 | n.a. |
| Dold, 1991 [50] | RCT | internal  | lung | I-IV | OS | 30 months | 114 / 113 | U c. Hg, Qu c Hg |
| Salzer, 1991 [51] | RCT | internal  | lung | I-IV | OS | 9 years  | 87 / 96 | n.a. |
| Schuppli, 1990 [52] | PCS | internal  | skin | n.a. | OS | ≥ 8 years | 84 / 114 | P c. Hg + BCG |
| Salzer, 1983 [53] | RCT | internal  | stomach | II-III | OS | 5 years | 35 / 37 | n.a. |
| Hoffmann & Hajto, 1982 [54] | RCS | internal  | breast | start of Iscador therapy directly after surgery  | OS | until death | 116 / 241 | n.a. |
| Hoffmann & Hajto, 1982 [54] | RCS | internal  | breast | start of Iscador therapy after metastatic relapse | OS | until death | 138 / 241 | n.a. |
| Leroi & Hajto,1982 [55] | HCT | literature | ovarian | I | OS | 5 years | 31 / 1688 | n.a. |
| Leroi & Hajto,1982 [55] | HCT | literature | ovarian | II | OS | 5 years | 18 / 1338 | n.a. |
| Salzer & Havelec, 1978 [56] | NRCT | internal  | lung | I | OS | ≥6.5 yearsafter surgery | 12 / 10 | n.a. |
| Salzer & Havelec, 1978 [56] | NRCT | internal  | lung | II | OS | ≥6.5 yearsafter surgery | 15 / 11 | n.a. |
| Salzer & Havelec, 1978 [56] | NRCT | internal  | lung | III | OS | ≥6.5 years after surgery | 10 / 19 | n.a. |
| Hoffmann, 1979 [44] | RCS | internal  | liver met | IV | OS | ≥1 year  | 188 / 122 | n.a. |
| Leroi, 1979 [45] | RCS | internal  | colorectal | inoperable / palliative surgery | OS | 17 months | 101 / 54 | n.a. |
| Leroi, 1977 [43] | RCS | internal  | breast | I | OS | 10 years | 149 / 107 | n.a. |
| Leroi, 1977 [43] | RCS | Internal  | breast | II | OS | 10 years | 170 / 121 | n.a. |
| Leroi, 1975 [42] | RCS | internal  | breast | I, II | OS | 5 years | 81 / 30 | n.a. |
| Günzler & Salzer, 1969[41] | CBA | internal historic | breast | I-III | OS | 5 years | 257 / 153 | n.a. |
| Fellmer, 1968 [39] | Q-RCT | internal | cervical | I-IV | OS | 2 years | 81 / 709 | M c. Ag |
| Günzler, Orsika & Salzer, 1968 [40] | RCS | internal  | stomach | LN- | OS | 5 years | 36 / 50 | n.a. |
| Günzler, Orsika & Salzer, 1968 [40] | RCS | internal  | stomach | LN+ | OS | 5 years | 31 / 51 | n.a. |
| Majewski & Bentele, 1963 [31] | Q-RCT | internal  | gynecological | cervix | OS | 2 years | 26 / 24 | n.a. |
| Majewski & Bentele, 1963 [31] | Q-RCT | internal  | gynecological | corpus uteri | OS | 2 years | 11 / 6 | n.a. |
| Majewski & Bentele, 1963 [31] | Q-RCT | internal  | gynecological | breast | OS | 2 years | 25 / 13 | n.a. |
| Majewski & Bentele, 1963 [31] | Q-RCT | internal  | gynecological | ovarian | OS | 2 years | 10 / 9 | n.a. |
| Abbreviations: BD: Breslow's depth; RCT: Randomized controlled trial; RCS: Retrospective cohort study; PCS: Prospective cohort study; HCT: Historically controlled trial; LN: lymph nodes; met: metastatic; NRCT: Non-randomized controlled trial; CBA: Controlled before-and-after study; Q-RCT: Quasi-randomized controlled trial; PRDFS: postrelapse disease-free survival; OS: overall survival; MFS: metastasis-free survival; M: Iscador M; P: Iscador P; Qu: Iscador Qu; c.: cum; Ag: Argentum; Hg: Hydrargyrum; n.a.: not available |